Genmab A/S GMAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:02 PM EDT
28.10quote price arrow down-0.37 (-1.30%)
Volume
5,906
Close
28.47quote price arrow down-0.09 (-0.32%)
Volume
448,129
52 week range
26.32 - 42.72
Loading...
  • Open28.75
  • Day High28.76
  • Day Low28.09
  • Prev Close28.56
  • 52 Week High42.72
  • 52 Week High Date07/28/23
  • 52 Week Low26.32
  • 52 Week Low Date02/13/24

Key Stats

  • Market Cap18.825B
  • Shares Out661.23M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-10.58

KEY STATS

  • Open28.75
  • Day High28.76
  • Day Low28.09
  • Prev Close28.56
  • 52 Week High42.72
  • 52 Week High Date07/28/23
  • 52 Week Low26.32
  • 52 Week Low Date02/13/24
  • Market Cap18.825B
  • Shares Out661.23M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-10.58

RATIOS/PROFITABILITY

  • EPS (TTM)0.98
  • P/E (TTM)29.11
  • Fwd P/E (NTM)25.88
  • EBITDA (TTM)763.382M
  • ROE (TTM)14.78%
  • Revenue (TTM)2.363B
  • Gross Margin (TTM)55.82%
  • Net Margin (TTM)26.42%
  • Debt To Equity (MRQ)2.44%

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Genmab A/S

 

Profile

MORE
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment...
Deirdre Connelly
Independent Chairman of the Board
Jan Van De Winkel Ph.D.
President, Chief Executive Officer
Anthony Mancini
Chief Operating Officer, Executive Vice President
Anthony Pagano
Chief Financial Officer, Executive Vice President
Judith Klimovsky M.D.
Executive Vice President, Chief Development Officer
Address
Kalvebod Brygge 43
Koebenhavn V
1560
Denmark

Top Peers

SYMBOLLASTCHG%CHG
ALNY
Alnylam Pharmaceuticals Inc
143.80-2.27-1.55%
NBIX
Neurocrine Biosciences Inc
138.97-1.12-0.80%
EXAS
Exact Sciences Corp
63.24-0.29-0.46%
BNTX
Biontech SE
88.09-0.40-0.45%
MEDP
Medpace Holdings Inc
397.56-9.59-2.36%